Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China’s pharmaceutical industry becomes increasingly important, Novo may be staring at a very uncomfortable question: what happens if synthetic semaglutide suddenly makes sense when Novo is the one making it?

In this week’s episode of The Weekly Dose, I dig into Novo’s long-running recombinant-versus-synthetic semaglutide argument, the lawsuits and FDA petitions built around it, and a clip from more than 16 months ago showing that we were covering this exact issue long before it became part of the mainstream conversation. Novo Warned Us About Synthetic Semaglutide_ Now This_.txt

We also break down Pfizer’s decision to kill two clinical-stage obesity drugs, including an oral GLP-1 acquired through its $10 billion Metsera deal, the strange science behind GIP receptor antagonism, and why Pfizer’s remaining obesity pipeline still deserves attention. Plus, Wall Street is looking at Eli Lilly’s obesity-fueled rally and asking just how big this market can get.

In this episode:

00:00 Novo’s synthetic semaglutide problem

02:00 VoaFit sponsor message

03:30 The 16-month-old On The Pen receipt

05:00 Recombinant vs. synthetic semaglutide

07:00 Novo’s FDA, legal, and political strategy

09:00 Pfizer kills two obesity drugs

11:00 What happened to Metsera’s oral pipeline?

13:00 The GIP agonist vs. antagonist paradox

15:00 Why China matters to Pfizer and Novo

17:00 Could Novo eventually make synthetic semaglutide?

18:30 What comes next for Lilly, Novo, and Pfizer

The big question: If Novo Nordisk eventually launches its own synthetically manufactured semaglutide, does that change how you view the arguments it has made against compounded semaglutide over the last several years?

Comment below. I want to know where you land.

More obesity medicine news and analysis: OnThePen.com

All my links, socials, and resources: linktr.ee/manonthemounjaro

This episode is sponsored by VoaFit. Learn more at voafit.com/otp.

#GLP1 #Semaglutide #Ozempic #Wegovy #NovoNordisk #CompoundedSemaglutide #ObesityMedicine #Pfizer #EliLilly #Mounjaro #Zepbound #Metsera

https://www.otplinks.comhttps://www.voafit.com/otpEpisode Referenced: https://www.youtube.com/watch?v=K8kaSoFCZ0c&t=41sThe retatrutide biologic fight is bigger than folks understand.This breakdown covers the current situation surrounding the retatrutide discussion. If you have been following the narrative, this episode provides context on why this biologic fight is garnering a lot of attention, and more importantly why it matters to every person watching this space. I first reported on these developments two years ago and offer insights gained from direct conversations with industry experts.We analyze the trajectory of this controversy to help you separate the signal from the noise. This episode serves as a vital update for anyone trying to track the retatrutide saga as it continues to evolve.Subscribe for weekly internet news breakdowns and let me know in the comments if you want more updates on this story as it develops.

Novo Nordisk just declared legal war on Eli Lilly as the battle over GLP-1 patients intensifies. But just because patients are being fought over does not mean they are being fought for.

In this episode, we break down Novo Nordisk’s lawsuit accusing Eli Lilly of misleading patients through advertisements comparing Zepbound and Mounjaro with Wegovy and Ozempic. The fight is not simply about which medication produces more weight loss. It is about who controls the information patients receive, which evidence gets highlighted, and what gets left in the fine print.

Then we examine STAT News’ investigation into LifeMD, a major telehealth company promoted by Novo as a legitimate pathway to GLP-1 treatment. Former employees alleged providers were pushed to process patients at breakneck speed, sometimes reviewing as many as 25 cases per hour, while refill queues, dose increases and patient messages piled up. LifeMD strongly disputes those allegations.

But this cannot become another simplistic story about telehealth being bad.

More than 100 million Americans are living with obesity, and only a small number of clinicians have dedicated obesity medicine expertise. The traditional healthcare system does not have enough specialists, appointment slots or geographic reach to provide every patient with an ideal, hour-long consultation.

So how altruistic can we afford to be about access?

Can we demand a perfect standard of care that most patients will never be able to reach? Or does scaling treatment too aggressively risk turning patients into transactions inside a prescription machine?

Access cannot become a shield for negligence. But perfection cannot become another form of gatekeeping.

The patient is being fought over. This episode asks what it would actually mean to fight for them.

Learn more and follow On The Pen: https://www.otplinks.com

This episode is sponsored by VoaFit, where I receive care for obesity and metabolic health.

https://www.voafit.com/otp to learn more!